Eli Lilly’s weight loss drug Zepbound shows promise as a sleep apnea treatment in late-stage trials

The pharmaceutical giant plans to present the trial data at an upcoming medical conference and submit them to the U.S. Food and Drug Administration mid-year. 



Source link